Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CHINOOK THERAPEUTICS, INC. (KDNY) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
08/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/11/2023 SC 13D Farallon Capital Partners, L.P. reports a 9.9% stake in Chinook Therapeutics, Inc.
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/11/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
08/11/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
08/11/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation",
"Amended and Restated Bylaws"
08/11/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
08/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart for Patients with IgA Nephropathy"
07/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/10/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
07/10/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
06/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Chinook Therapeutics to Present Updated Data from Zigakibart Phase 1/2 Trial in Patients with IgA Nephropathy at the 60 th European Renal Association Congress"
06/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/12/2023 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
06/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/12/2023 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Chinook Therapeutics, Inc., Novartis AG and Cherry Merger Sub Inc",
"Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "CHINOOK THERAPEUTICS, INC. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Collaboration and license revenue $ 1,828 $ 2,697 Operating expenses: Research and development 50,883 26,252 General and administrative 11,404 7,868 Change in fair value of contingent consideration and contingent value rights liabilities 526 Amortization of intangible assets 433 429 Total operating expenses 63,246 33,511 Loss from operations Investment and other income , net 3,102 Loss before income taxes and equity method investment loss Equity method investment loss Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 70..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy